Keros Therapeutics, Inc. (KROS)

Name: Keros Therapeutics, Inc. (KROS) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001664710 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Keros Therapeutics, Inc. reported revenue of $244.06M. Over the twelve months to 2026-06-30, revenue was $15.01M.

Key ratios (year ended 2025-12-31)

27.7%

Operating margin

35.7%

Net margin

28.7%

Return on year-end equity

n/m

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-29

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	$15.01M	$244.06M	$3.55M	$151.0K	$0	$20.10M	$0	$10.00M
R&D Expense	$75.86M	$129.64M	$173.63M	$135.26M	$87.27M	$55.14M	$33.86M	$17.38M
Operating Income	-$101.47M	$67.57M	-$210.83M	-$169.94M	-$114.79M	-$56.37M	-$46.66M	-$10.56M
Net Income	-$83.16M	$87.01M	-$187.35M	-$152.99M	-$104.68M	-$58.74M	-$45.36M	-$12.34M
EPS (Diluted)	n/a	$2.30	-$5.00	-$5.20	-$4.15	-$2.52	-$2.93	n/a
Total Assets	$287.60M	$338.02M	$615.89M	$370.02M	$306.78M	$255.25M	$269.44M	$10.96M
Total Liabilities	$25.28M	$34.89M	$44.33M	$37.81M	$29.36M	$12.08M	$7.72M	$10.46M
Shareholders' Equity	$262.32M	$303.13M	$571.55M	$332.21M	$277.42M	$243.17M	$261.72M	-$19.45M
Cash & Equivalents	$257.61M	$287.42M	$559.93M	$331.15M	$279.05M	$230.04M	$265.88M	$7.02M
Operating Cash Flow	-$47.99M	$107.50M	-$160.87M	-$124.51M	-$70.06M	-$62.15M	-$36.89M	-$16.00M
Capital Expenditures	$494.0K	$1.55M	$1.93M	$2.46M	$1.24M	$1.02M	$294.0K	$271.0K
Free Cash Flow	-$48.49M	$105.95M	-$162.80M	-$126.97M	-$71.30M	-$63.17M	-$37.19M	-$16.27M
Share Repurchases	n/a	$375.00M	$0	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	19.83M	19.54M	40.55M	31.84M	27.54M	23.97M	23.19M	2.43M
Weighted Average Diluted Shares	n/a	37.86M	37.44M	29.45M	25.24M	23.33M	15.51M	n/a
EPS (Basic)	n/a	$2.34	-$5.00	-$5.20	-$4.15	-$2.52	-$2.93	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView